# US 2003/0212007 A1 · Lignan complex derived from flaxseed as hypercholesterolemic and anti-atherosclerotic agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0212007 A1
- Document ID: US20030212007A1
- Status: Published application
- Kind: A1
- Application number: 10/141,860
- Filed: 2002-05-10
- Published: 2003-11-13
- Earliest claimed: 2002-05-10
- Assignees: University of Saskatchewan Technologies Inc.
- Inventors: Kailash Prasad
- Web page: https://patentgrep.com/patent/US20030212007A1

## CPC

- A61K 51/1206: {Administration of radioactive gases, aerosols or breath tests}
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method is described for treating hypercholesterolemic atherosclerosis or for reducing total cholesterol while raising high-density lipoportoein cholesterol. It involves administering to a patient a substantially pure complex derived from flaxseed and containing secoisolariciresinol diglucoside (SDG), cinnamic acid glucosides and hydroxymethyl glutaric acid.

## Claims

### Claim 1

A method for treating hypercholesterolemic atherosclerosis or for reducing total cholesterol while raising high-density lipoprotein cholesterol which comprises administering to a patient an effective amount of a complex in substantially pure form derived from flaxseed and containing secoisolariciresinol diglucoside (SDG), cinnamic acid glucosides and hydroxymethyl glutaric acid.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the complex has a purity of at least 95%.

### Claim 3 (depends on 2)

A method according to claim 2 wherein the complex contains about 34 to 37% by weight of SDG, about 15 to 21% by weight of cinnamic acid glucosides and about 9.6 to 11.0% by weight hydroxymethyl glutaric acid.

### Claim 4 (depends on 3)

A method according to claim 3 wherein the cinnamic acid glucosides include coumaric acid glucoside and ferulic acid glucoside.

### Claim 5 (depends on 2)

A method according to claim 2 wherein the complex is administered orally in a daily dosage of about 20 to 60 mg per kg of body weight.
